S'abonner à DNDi_HQ sur Twitter
Strengthening Capacity / LEAP Platform

LEAP Platform

  • Print
 LEISHMANIASIS EAST AFRICA PLATFORM (LEAP)

Founded: 2003 in Khartoum, Sudan
Members: Center for Clinical Research, Kenya; Medical Research Institute, Kenya; Ministry of Health, Kenya; Institute of Endemic Diseases, University of Khartoum, Sudan; Federal Ministry of Health, Sudan; Addis Ababa University, Ethiopia; Gondar University, Ethiopia; Federal Bureau of Health, Ethiopia; Makerere University, Uganda; Ministry of Health, Uganda; Médecins Sans Frontières; i+ Solutions; OneWorldHealth (OWH); AMC/KIT/University of Slotervaart, Amsterdam, The Netherlands; London School of Hygiene and Tropical Medicine (LSHTM), UK. 

Funding: Department for International Development (DFID), UK; Federal Ministry of Education and Research (BMBF through KfW), Germany; Médecins Sans Frontières/Doctors without Borders, International; Medicor Foundation, Liechtenstein; Ministry of Foreign Affairs (DGIS), The Netherlands; Ministry of Foreign and European Affairs (MAEE), France; Region of Tuscany, Italy; Spanish Agency for International Development Cooperation (AECID), Spain; Swiss Agency for Development and Cooperation (SDC), Switzerland

 
  • Approx. 60 individual members, representing over 20 institutions
  • Over 1,300 patients enrolled in clinical trials by the end of 2011
  • Approximately 700-800 patients treated outside clinical trials in 2011
  • 1000 patients on Pharmacovigilance Phase IV study
 


Objectives: The overall aim of the platform is to strengthen clinical research capacity, which is lacking in part due to the remoteness and geographic spread of the patients, most of whom live in the most impoverished regions of Africa. This platform also serves as a base for ongoing educational cooperation between the countries in the East African region and standardization of procedures and practices within the region, as far as is possible within the confines of local regulations. LEAP evaluates, validates, and registers new treatments that address regional needs for VL. 
 

 


DNDi Newsletters about the platform:


Press releases about the platform:

  • Press release: Geneva, 22 November 2004, DNDi Clinical Trials for Paromomycin begin in Sudan.

 



Except where otherwise noted, content on this site is licensed under a Creative Commons Attribution-Noncommercial-Share Alike 2.5 Switzerland License